

List of Tables

<i>Table</i>	<i>Title</i>	<i>page</i>
3.1	SMILES, InChI, and IUPAC representation of Levobunolol	17
3.2	List of 2D chemical family and their properties.	18
3.3	List of 3D chemical family and their properties.	20
5.1	Feature and AUC are shown for measurement of side effects prediction computed using 'unconstrained canonical correlation analysis'.	33
5.2	AUC measured of 2D and 3D chemical profile along with target profile. Integration of target profile with 2D and 3D chemical profiles have been referred as 2D+ and 3D+.	35
5.3	Relevance of drug hubs. While generally neither the drugs causing most side effects nor those regulating large number of drugs seem to be critical for prediction efficacy, with increasing number of drugs removed, the latter seem to be relevant for prediction.	36
5.4	Relevance of promiscuous profile hubs. While removal of profiles with most prevalent side effects does not affect the prediction efficacy significantly, the profiles of most promiscuous targets are critical.	36
5.5	3D Chemical parameter pairs with best correlation with side effects.	39
5.6	2D Chemical parameter pairs with best correlation with side effects.	39
7.1	List of side effects for each of the side effects class linked to an organ/system.	50
7.2	'Blood' Class: Mean and standard deviation of Weighted Performance corresponding to different sample size and proportion of known side effects.	54
7.3	'Blood' Class: Three best groups with various proportion of known side effects and their performance.	56
7.4	'Blood' Class: A ranked list of critical side effects obtained with sample size 1000.	57
7.5	'Eye' Class: A ranked list of critical side effects obtained with sample size 1000.	58
7.6	'Eye' Class: Three best groups with various proportion of known side effects and their performance.	59
7.7	'Abdominal' Class: A ranked list of critical side effects obtained with sample size 1000.	60
7.8	'Abdominal' Class: Three best groups with various proportion of known side effects and their performance.	60
7.9	'Hepatic' Class: A ranked list of critical side effects obtained with sample size 1000.	62
7.10	'Hepatic' Class: Three best groups with various proportion of known side effects and their performance.	62
7.11	'Gastrointestinal' Class: A ranked list of critical side effects obtained with sample size 1000.	64
7.12	'Gastrointestinal' Class: Three best groups with various proportion of known side effects and their performance.	64
7.13	'Kidney' Class: A ranked list of critical side effects obtained with sample size 1000.	65
7.14	'Kidney' Class: Three best groups with various proportion of known side effects and their performance.	66
7.15	'Nose' Class: A ranked list of critical side effects obtained with sample size 1000.	66
7.16	'Nose' Class: Three best groups with various proportion of known side effects and their performance.	67
7.17	Comparison of CCA and Ridge regression strategies in predicting 'unknown side effects', starting with the knowledge of 30% 'known side effects' for different organ/system.	68
8.1	Statistics for adverse reactions related to 'Nose' for different cut-offs of redundancy.	72
8.2	Statistics for adverse reactions related to 'Abdomen' for different cut-offs of redundancy.	72
8.3	Statistics for adverse reactions related to 'Eye' for different cut-offs of redundancy.	73
8.4	2D features closely linked with 'Eye' related side effects, obtained using PCCA.	77
8.5	2D features closely linked with 'Nose' related side effects, obtained using PCCA.	78
8.6	2D features closely linked with 'Abdomen' related side effects, obtained using PCCA.	79
A.1	Illustration of vector differentiation with Numerator and Denominator layout.	83
A.2	Illustration of different formulae with Numerator layout derivation.	83
B.1	'Eye' Class: Best sets (Top 5) of 2D Chemical features and their performance with redundancy cut-off of ≤ 0.6 . For mapping the index listed in the table corresponding to 2D features, please refer to Table 3.2.	85
B.2	'Eye' Class: Best sets (Top 5) of 2D Chemical features and their performance with redundancy cut-off of ≤ 0.7 . For mapping the index listed in the table corresponding to 2D features, please refer to Table 3.2.	86

B.3	'Eye' Class: Best sets (Top 5) of 2D Chemical features and their performance with redundancy cut-off of ≤ 0.8 . For mapping the index listed in the table corresponding to 2D features, please refer to Table 3.2.	86
B.4	'Nose' Class: Best sets (Top 5) of 2D Chemical features and their performance with redundancy cut-off of ≤ 0.6 . For mapping the index listed in the table corresponding to 2D features, please refer to Table 3.2.	87
B.5	'Nose' Class: Best sets (Top 5) of 2D Chemical features and their performance with redundancy cut-off of ≤ 0.7 . For mapping the index listed in the table corresponding to 2D features, please refer to Table 3.2.	88
B.6	'Nose' Class: Best sets (Top 5) of 2D Chemical features and their performance with redundancy cut-off of ≤ 0.8 . For mapping the index listed in the table corresponding to 2D features, please refer to Table 3.2.	88
B.7	'Abdominal' Class: Best sets (Top 5) of 2D Chemical features and their performance with redundancy cut-off of ≤ 0.8 . For mapping the index listed in the table corresponding to 2D features, please refer to Table 3.2.	89
B.8	'Abdominal' Class: Best sets (Top 5) of 2D Chemical features and their performance with redundancy cut-off of ≤ 0.8 . For mapping the index listed in the table corresponding to 2D features, please refer to Table 3.2.	90
B.9	'Abdominal' Class: Best sets (Top 5) of 2D Chemical features and their performance with redundancy cut-off of ≤ 0.8 . For mapping the index listed in the table corresponding to 2D features, please refer to Table 3.2.	90